Research Topics
Species | Bert O'NeilSummaryAffiliation: University of North Carolina Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapyJanine M Davies
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
Radiat Oncol 6:114. 2011..Our objective was to explore the relationships of KRAS and BRAF mutation status with p-AKT and p-ERK and outcomes in RC...
Gemcitabine radiosensitization for rectal cancer: step forward or dance step?BERT H O'NEIL
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Cancer J 11:110-2. 2005- Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can)BERT H O'NEIL
UNC Lineberger Comprehensive Cancer Center, 3009 Old Clinic Building, CB 7305, Chapel Hill, NC 27599 7305, USA
Semin Oncol 32:35-42. 2005..Chemotherapy is likely to remain a central element of the treatment strategy. Our understanding of its current role is discussed in this article... - High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic historyBERT H O'NEIL
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
J Clin Oncol 25:3644-8. 2007.... - Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomasBERT H O'NEIL
Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Oncology 72:97-104. 2007..Recent information has implicated IkappaB family members (e.g. Bcl-3) as possible mediators of NF-kappaB activation. Therefore, we examined the expression of all NF-kappaB family members and downstream targets in HCC... 
Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapyBERT H O'NEIL
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
Oncologist 12:1425-32. 2007..This article briefly discusses the management of earlier stage HCC, then focuses on newer agents with promise, particularly sorafenib, a drug that appears to be the new standard of care for advanced disease...- Current options for the management of rectal cancerBERT H O'NEIL
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
Curr Treat Options Oncol 8:331-8. 2007.... - Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinomaBERT H O'NEIL
University of North Carolina, 170 Manning Drive, Chapel Hill, NC 27599 730, USA
J Clin Oncol 29:2350-6. 2011..CONCLUSION In this study of selumetinib for patients with HCC, no radiographic responses were seen and time to progression was short, which suggests minimal single-agent activity despite evidence of suppression of target activation... - Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trialsBERT H O'NEIL
Division of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
Oncologist 13:1074-83. 2008..Recent innovations in chemotherapy for mCRC are reviewed, with a focus on emerging data that may significantly improve both survival and quality of life for patients with CRC in the future... - Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment optionsJanine Marie Davies
University of North Carolina, Division of Hematology Oncology, 170 Manning Dr, CB 7305, Chapel Hill, NC 27599, USA
Expert Opin Investig Drugs 18:913-9. 2009.... - Phase I trial of vinflunine and pemetrexed in refractory solid tumorsHanna K Sanoff
Department of Medicine, Division of Hematology Oncology, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Invest New Drugs 29:131-6. 2011..Pemetrexed has at least additive activity with other vincas. A phase I trial was undertaken to assess the safety of vinflunine and pemetrexed in patients with refractory solid tumors... - Targeted therapies for hepatocellular carcinomaMatthew R Skelton
Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Clin Adv Hematol Oncol 6:209-18. 2008..Here we review recent and ongoing studies of new therapeutic agents for HCC, including the small-molecule tyrosine kinase inhibitors, monoclonal antibodies, and combinations of these drugs... - A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or HigherUsman Shah
Division of Medical Oncology, University of North Carolina, Chapel Hill, NC
Gastrointest Cancer Res 3:45-8. 2009.... - Targeted therapy in colorectal cancerSupriya Rajpal
University of California, San Francisco, Division of Hematology Oncology, 505 Parnassus Avenue, Box 1270, San Francisco, CA 94143 1270, USA
Clin Adv Hematol Oncol 4:124-32. 2006..Further advances in the treatment of CRC are expected through continued scientific investigation and well-designed clinical trials... - Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinomaAlan P Venook
Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
Cancer 103:2435-46. 2005..Numerous molecules targeting the epidermal growth factor receptor have been investigated as therapeutic agents and appear to herald a shift in the treatment paradigm for colorectal carcinoma... - Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207J E Rosenberg
Division of Hematology and Oncology, University of California, San Francisco Cancer Center, San Francisco, CA 94115, USA
Ann Oncol 19:946-50. 2008..Response rates to second-line chemotherapy for advanced UC are low and response duration is short. Bortezomib is a proteasome inhibitor with preclinical activity against UC... - Cetuximab in the treatment of colorectal cancerRichard M Goldberg
Division of Hematology/Oncology, University of North Carolina, Chapell Hill, NC, USA
Clin Adv Hematol Oncol 2:1-10; quiz 11-12. 2004 - A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancerAndrew H Ko
Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
Int J Radiat Oncol Biol Phys 68:809-16. 2007..We conducted a Phase II nonrandomized trial to evaluate sequential chemotherapy followed by chemoradiation in this patient population... - Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114Jeffrey A Meyerhardt
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 22:648-57. 2004..To study the relationship between body mass index (BMI) and rates of sphincter-preserving operations, overall survival, cancer recurrence, and treatment-related toxicities in patients with rectal cancer... - Complications associated with neoadjuvant radiotherapy in the multidisciplinary treatment of retroperitoneal sarcomasAbigail S Caudle
Department of Surgery, Division of Surgical Oncology, University of North Carolina School of Medicine, 3010 Old Clinic Building, CB 7213, Chapel Hill, NC 27599, USA
Ann Surg Oncol 14:577-82. 2007..Preoperative RT offers theoretical advantages in the multidisciplinary care of RPS. The purpose of our study was to evaluate our experience using preoperative radiotherapy (PRT) in the treatment of RPS... - Cancer and leukemia group B gastrointestinal cancer committeeRichard M Goldberg
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Clin Cancer Res 12:3589s-95s. 2006..Future efforts aim to evolve new standards of care, evaluate new therapies, and answer relevant biological questions in gastrointestinal cancer... - Rectal cancer radiotherapyShelileah Ramsey
Department of Radiation Oncology, University of North Carolina School of Medicine, UNC Lineberger Clinical Cancer Center, Chapel Hill, NC 27599 7512, USA
Cancer J 13:204-9. 2007.... - Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901David P Ryan
Massachusetts General Hospital Cancer Center, Boston MA 02114, USA
J Clin Oncol 24:2557-62. 2006..This phase I/II study evaluated the addition of weekly oxaliplatin to preoperative continuous infusion fluorouracil (FU) and external-beam radiation therapy (RT) in patients with locally advanced rectal adenocarcinoma... - Dose optimization via index-dose gradient minimizationSha X Chang
Department of Radiation Oncology, University of North Carolina at Chapel Hill, 27599 7512, USA
Med Phys 29:1130-46. 2002..The primary advantages of our optimization algorithm include computational efficiency, intensity modulation selection choice, and performance reliability for a wide range of clinical beam setups and optimization objectives... - Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysisLeonard L Gunderson
Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
Int J Radiat Oncol Biol Phys 54:386-96. 2002..For future trial design, it may be preferable to perform separate studies, or a planned statistical analysis, for the "intermediate-risk" vs. the "moderately high" or "high-risk" subsets of patients... - Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 StudyJeffrey A Meyerhardt
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 22:166-74. 2004..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain... - Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysisLeonard L Gunderson
Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
J Clin Oncol 22:1785-96. 2004..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies... - Patient selection, realism, and randomized clinical trialsJoel E Tepper
J Clin Oncol 22:3215-7. 2004 - Staging of colorectal cancer: past, present, and futureJanet K Horton
Department of Radiation Oncology, University of North Carolina, Chapel Hill 27599, USA
Clin Colorectal Cancer 4:302-12. 2005..Staging in the future is likely to be a complicated combination of anatomic and biologic markers used together in mathematic modeling to group patients into prognostic risk groups, which can be used to guide tailored therapy... - Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysisNancy N Baxter
Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
Int J Radiat Oncol Biol Phys 61:426-31. 2005..To determine the impact of preoperative radiotherapy (RT) on the accuracy of lymph node staging (LNS). Preoperative RT is a well-established component of rectal cancer treatment but its impact on LNS is unknown... - An embarrassment of riches: neoadjuvant therapy of rectal cancerJoel E Tepper
J Clin Oncol 23:1339-41. 2005 - In vivo intraoperative radiotherapy: a novel approach to radiotherapy for early stage breast cancerKaryn B Stitzenberg
Department of Surgery, University of North Carolina, Chapel Hill, NC, USA
Ann Surg Oncol 14:1515-6. 2007..We are investigating the feasibility of partial breast irradiation using a single fraction of IORT delivered to the tumor in vivo prior to surgical resection... - Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiativeDavid E Morris
Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC 27514, USA
Int J Radiat Oncol Biol Phys 62:3-19. 2005.... - Rectal cancer: can we throw away the scalpel?Michael O Meyers
Ann Surg Oncol 12:95-7. 2005 - Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancerJoel E Tepper
Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
Semin Radiat Oncol 12:187-95. 2002..These should be used as guides for defining appropriate field arrangements for the adjuvant postoperative therapy of gastric cancer... - ASTRO 45th annual meeting presidential address: Medicine's arrow, medicine's cycle: lessons for radiation oncologyJoel E Tepper
Int J Radiat Oncol Biol Phys 59:623-33. 2004 - Postoperative irradiation for rectal cancer increases the risk of small bowel obstruction after surgeryNancy N Baxter
Department of Surgery, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
Ann Surg 245:553-9. 2007..To determine the risk of small bowel obstruction (SBO) after irradiation (RT) for rectal cancer.. - Risk of pelvic fractures in older women following pelvic irradiationNancy N Baxter
Division of Colon and Rectal Surgery, Department of Surgery, University of Minnesota, Minneapolis 55455, USA
JAMA 294:2587-93. 2005..Pelvic fractures, including hip fractures, are a major source of morbidity and mortality in older women. Although therapeutic pelvic irradiation could increase the risk of such fractures, this effect has not been studied... - Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreasA William Blackstock
Radiation Oncology, Wake Forest University Comprehensive Cancer Center, Winston Salem, NC 277516, USA
Int J Gastrointest Cancer 34:107-16. 2003..Determine the safety and efficacy of twice weekly gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with surgically staged, locally advanced pancreatic cancer... - Is less more? Lessons in radiation schedules in breast cancerCarolyn I Sartor
J Natl Cancer Inst 94:1114-5. 2002 - Increased risk of rectal cancer after prostate radiation: a population-based studyNancy N Baxter
Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
Gastroenterology 128:819-24. 2005..Radiation therapy for prostate cancer has been associated with an increased rate of pelvic malignancies, particularly bladder cancer. The association between radiation therapy and colorectal cancer has not been established...
Research Grants
- Radiation-induced signaling and treatment resistanceBERT O NEIL; Fiscal Year: 2007..The long-term goal of our research is to apply drugs that target tumor but not normal tissue in addition to radiation to improve the effectiveness of radiation on rectal cancer. ..